title: Poor prognosis for P2RY8-CRLF2 fusion but not for CRLF2 over-expression in children with intermediate risk B-cell precursor acute lymphoblastic leukemia.
abstract: Pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL) has achieved an 80% cure rate as a result of a risk-adapted therapy largely based on minimal residual disease (MRD) monitoring. However, relapse is still the most frequent adverse event, occurring mainly in the patients with intermediate MRD levels (intermediate risk, IR), emphasizing the need for new prognostic markers. We analyzed the prognostic impact of cytokine receptor-like factor 2 (CRLF2) over-expression and P2RY8-CRLF2 fusion in 464 BCP-ALL patients (not affected by Down syndrome and BCR-ABL negative) enrolled in the AIEOP-BFM ALL2000 study in Italy. In 22/464 (4.7%) samples, RQ-PCR showed CRLF2 over-expression (≥20 times higher than the overall median). P2RY8-CRLF2 fusion was detected in 22/365 (6%) cases, with 10/22 cases also showing CRLF2 over-expression. P2RY8-CRLF2 fusion was the most relevant prognostic factor independent of CRLF2 over-expression with a threefold increase in risk of relapse. Significantly, the cumulative incidence of relapse of the P2RY8-CRLF2 + patients in the IR group was high (61.1% ± 12.9 vs 17.6% ± 2.6, P<0.0001), similar to high-risk patients in AIEOP-BFM ALL2000 study. These results were confirmed in a cohort of patients treated in Germany. In conclusion, P2RY8-CRLF2 identifies a subset of BCP-ALL patients currently stratified as IR that could be considered for treatment intensification.
authors.affiliation: Centro Ricerca Tettamanti, Clinica Pediatrica, Università di Milano Bicocca, Ospedale San Gerardo, Monza, Italy.
authors.forename: C
authors.initials: C
authors.lastname: Palmi
authors.forename: E
authors.initials: E
authors.lastname: Vendramini
authors.forename: D
authors.initials: D
authors.lastname: Silvestri
authors.forename: G
authors.initials: G
authors.lastname: Longinotti
authors.forename: D
authors.initials: D
authors.lastname: Frison
authors.forename: G
authors.initials: G
authors.lastname: Cario
authors.forename: C
authors.initials: C
authors.lastname: Shochat
authors.forename: M
authors.initials: M
authors.lastname: Stanulla
authors.forename: V
authors.initials: V
authors.lastname: Rossi
authors.forename: A M
authors.initials: AM
authors.lastname: Di Meglio
authors.forename: T
authors.initials: T
authors.lastname: Villa
authors.forename: E
authors.initials: E
authors.lastname: Giarin
authors.forename: G
authors.initials: G
authors.lastname: Fazio
authors.forename: A
authors.initials: A
authors.lastname: Leszl
authors.forename: M
authors.initials: M
authors.lastname: Schrappe
authors.forename: G
authors.initials: G
authors.lastname: Basso
authors.forename: A
authors.initials: A
authors.lastname: Biondi
authors.forename: S
authors.initials: S
authors.lastname: Izraeli
authors.forename: V
authors.initials: V
authors.lastname: Conter
authors.forename: M G
authors.initials: MG
authors.lastname: Valsecchi
authors.forename: G
authors.initials: G
authors.lastname: Cazzaniga
authors.forename: G
authors.initials: G
authors.lastname: Te Kronnie
mesh_terms: D050939:Gene Fusion; D006801:Humans; D015452:Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / Q000235:genetics*; D011379:Prognosis; D016016:Proportional Hazards Models; D018121:Receptors, Cytokine / Q000235:genetics / Q000502:physiology*; D018048:Receptors, Purinergic P2 / Q000235:genetics*; D012008:Recurrence; D012307:Risk Factors
chemical_list: C498762:CRLF2 protein, human; D018121:Receptors, Cytokine; D018048:Receptors, Purinergic P2